Iqvia vs Medpace
IQV and MEDP side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IQV and MEDP compare
Iqvia is the larger company, worth 2.3 times as much as Medpace ($42.5B against $18.3B).
On earnings, Iqvia is cheaper: it trades at 31.3× trailing earnings, against 36.2× for Medpace.
Medpace grew revenue faster over the last twelve months (20.4% versus 8.8% for Iqvia).
Medpace keeps more of each dollar of sales as profit, with a net margin of 18.2% compared with 8.1% at Iqvia.
Medpace scores higher on the StockData Score (14 against 9 for Iqvia), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IQV | MEDP |
|---|---|---|
| Size and price | ||
| Market cap | $42.5B | $18.3B |
| Share price | $257.60 | $653.09 |
| Change, 1 year | 16.8% | 10.7% |
| Change, 5 years | −1.7% | 211% |
| Beta (5Y) | 0.63 | 0.33 |
| Employees | 93K | 6,200 |
| StockData Score | ||
| Total score | 9 | 14 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 31.3× (better) | 36.2× |
| P/S | 2.5× (better) | 6.4× |
| P/B | 6.4× (better) | 31.2× |
| EV/EBITDA | 16.4× (better) | 28.9× |
| P/FCF | 20.4× (better) | 27.4× |
| PEG | 2.82 | 1.29 (better) |
| FCF yield | 4.9% (better) | 3.7% |
| Fair value | $226.21 | $459.97 |
| Margin of safety | −13.9% (better) | −42.0% |
| Growth | ||
| Revenue growth (TTM) | 8.8% | 20.4% (better) |
| Revenue growth, 5Y average | 7.5% | 22.3% (better) |
| Net income growth (TTM) | 8.7% | 19.6% (better) |
| EPS growth (TTM) | 12.9% | 26.1% (better) |
| EPS growth, 5Y average | 40.5% (better) | 31.8% |
| Profitability | ||
| Gross margin | 33.1% | – |
| Operating margin | 12.8% | 21.4% (better) |
| Net margin | 8.1% | 18.2% (better) |
| FCF margin | 12.0% | 23.5% (better) |
| Return on equity | 21.7% | 118% (better) |
| Return on invested capital | 9.4% | – |
| Financial health | ||
| Debt / equity | 2.41 (better) | 0.00 |
| Net debt / EBITDA | 3.97 | – |
| Interest coverage | 2.8× | – |
| Current ratio | 0.83 | 0.83 (better) |
| Altman Z-score | 2.21 | 8.13 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | 2.7% (better) | 1.6% |
| Shareholder yield | 2.7% (better) | 1.6% |
| Ownership | ||
| Held by institutions | 95.2% | 88.3% |
| Held by insiders | 1.1% | 20.0% |
| Insider net buying, 12 months | −$39.3M (better) | −$262M |
| Superinvestors holding | 3 (better) | 2 |
| Short interest, % of float | 1.9% | 6.2% |
Go deeper
- IQV stock overview
- IQV income statement
- IQV valuation and score
- MEDP stock overview
- MEDP income statement
- MEDP valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.